Physician profile
Serge Thys
NPI 1841554797
$1,143.75
in general payments reported to CMS, 2019-2025
18 companies · $402 in 2025
The $402 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $321 · 2020: $40.74 · 2022: $135 · 2023: $133 · 2024: $112 · 2025: $402.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $647.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $647.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $275.20 | 2022-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $210.00 | 2025 | |
| Gilead Sciences, INC. | $81.35 | 2019 | |
| Abbvie INC. | $71.94 | 2019-2022 | |
| Lundbeck LLC | $67.15 | 2019-2024 | Rexulti |
| Exact Sciences Corporation | $60.00 | 2023-2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $53.29 | 2019 | |
| Ironshore Pharmaceuticals INC. | $52.92 | 2019-2023 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $49.51 | 2023-2025 | Qelbree, Qelbree |
| Janssen Scientific Affairs, LLC | $46.91 | 2024 | Invega Sustenna |
| Merck Sharp & Dohme LLC | $32.93 | 2019-2024 | |
| Theratechnologies INC. | $30.90 | 2019 | |
| Glaxosmithkline, LLC. | $23.90 | 2023 | Shingrix |
| Sunovion Pharmaceuticals INC. | $22.08 | 2020 | |
| Nabriva Therapeutics, Plc | $18.66 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $18.10 | 2019 | |
| Hologic Sales and Service, LLC | $16.30 | 2023 | Thinprep 2000 Processor, Aptima |
| Allergan, INC. | $12.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Serge Thys listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.